We propose continuation of a multidisciplinary research training program in neuro-oncology based at the Massachusetts General Hospital Cancer Center. The primary objective of this two-year program is to train physician-scientists capable of providing a critical bridge between the biological sciences and experimental therapeutics. In order to achieve this objective the training program emphasizes a didactic curriculum in clinical research methodology, mentor-supervised clinical and basic science research experiences, and ongoing scholar monitoring and feedback. All scholars are also assigned a clinical trial project during the course of the training program. All 44 clinical and laboratory mentors participating in this training program have extensive experience in neuro-oncology research and training, active research funding and provide an excellent resource for scholars interested in translational research. All scholars have access to senior biostatistical and computing support on all projects. An internal advisory committee chaired by the program director, as well as an external advisory committee, oversee the training program. An Alumni Advisory Committee will be added to the governance structure of the grant in this new cycle. In addition to clinical and basic science research facilities at the Massachusetts General Hospital, the Brigham and Women's Hospital, the Dana-Farber Cancer Institute and Harvard Medical School, the program includes investigators at the Children's Hospital, the Harvard School of Public Health and the Massachusetts Institute of Technology. There is no overlap between our unique grant focused on nervous system tumors and other training grants at Harvard focused on medical oncology. Candidates include physicians completing clinical training in adult and pediatric neuro-oncology, adult and pediatric neurosurgical oncology, adult and pediatric medical oncology and radiation oncology. A qualified pool of applicants from these disciplines can be expected to grow from existing and developing sources. Each trainee has a dedicated two-year block for research and training with minimal clinical responsibilities. Four postdoctoral positions are requested per year for five years with each scholar making a two-year commitment to investigation. Applicants will be solicited through advertisements and active recruitment by the program and individual faculty. We believe that the proposed training program capitalizes on a group of outstanding mentors and superb training facilities and will have the capability to produce productive patient-oriented researchers in neuro-oncology. Since the original award 15 years ago the quality of the program has steadily improved based upon such metrics as diversity in scholar clinical specialties, scholar publications, scholar academic positions, schola leadership of national clinical trials and scholar grant awards.

Public Health Relevance

This grant is designed to train brain cancer specialists in the methods of research. The training program will expose the physician to coursework and hands-on experience in the laboratory. It is anticipated that after their training our program graduates will continue to advance the field by developing clinical trials to test new treatments for brain cancer patients.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Physician Scientist Award (Program) (PSA) (K12)
Project #
5K12CA090354-19
Application #
9771372
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Bian, Yansong
Project Start
2001-09-26
Project End
2021-08-31
Budget Start
2019-09-01
Budget End
2020-08-31
Support Year
19
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Massachusetts General Hospital
Department
Type
DUNS #
073130411
City
Boston
State
MA
Country
United States
Zip Code
02114
Hess, Clayton B; Indelicato, Daniel J; Paulino, Arnold C et al. (2018) An Update From the Pediatric Proton Consortium Registry. Front Oncol 8:165
Andronesi, Ovidiu C; Arrillaga-Romany, Isabel C; Ly, K Ina et al. (2018) Pharmacodynamics of mutant-IDH1 inhibitors in glioma patients probed by in vivo 3D MRS imaging of 2-hydroxyglutarate. Nat Commun 9:1474
Miller, Julie J; Wick, Wolfgang (2018) What's New in Grade II and Grade III Gliomas? Semin Neurol 38:41-49
Wang, Nancy; Bertalan, Mia S; Brastianos, Priscilla K (2018) Leptomeningeal metastasis from systemic cancer: Review and update on management. Cancer 124:21-35
Filbin, Mariella G; Tirosh, Itay; Hovestadt, Volker et al. (2018) Developmental and oncogenic programs in H3K27M gliomas dissected by single-cell RNA-seq. Science 360:331-335
Wang, Nancy; Osswald, Matthias (2018) Meningiomas: Overview and New Directions in Therapy. Semin Neurol 38:112-120
Tateishi, Kensuke; Higuchi, Fumi; Miller, Julie J et al. (2017) The Alkylating Chemotherapeutic Temozolomide Induces Metabolic Stress in IDH1-Mutant Cancers and Potentiates NAD+ Depletion-Mediated Cytotoxicity. Cancer Res 77:4102-4115
Venteicher, Andrew S; Tirosh, Itay; Hebert, Christine et al. (2017) Decoupling genetics, lineages, and microenvironment in IDH-mutant gliomas by single-cell RNA-seq. Science 355:
Brastianos, Priscilla K; Santagata, Sandro (2016) ENDOCRINE TUMORS: BRAF V600E mutations in papillary craniopharyngioma. Eur J Endocrinol 174:R139-44
Ohnishi, Takashi; Nakamura, Yuka; Tanaka, Toru et al. (2016) Deformable image registration between pathological images and MR image via an optical macro image. Pathol Res Pract 212:927-936

Showing the most recent 10 out of 45 publications